Biohaven is planning a pivotal study of BHV-1300 in Graves' disease in 2026. Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDEâ"¢ and next-generation, highly selective TRAPâ"¢ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to da ...